Phase 2
Completed N=661
Treatment of Covid-19 With a Herbal Compound, Xagrotin
Source: ClinicalTrials.gov NCT05017493 ↗Enrolled (actual)
661
Serious AEs
1.7%
Results posted
Dec 2021
Primary outcomePrimary: Mortality — 2; 10 participants
Summary
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mortality |
2; 10 | — |
| SECONDARY Duration of Disease From Beginning of Treatment |
9.9; 18.1 | — |
| SECONDARY Hospitalization |
11; 57 | — |
| SECONDARY Duration of Hospitalization When Occurred |
5.56; 5.5 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 or higher
- Newly diagnosed (no longer than 10 days)
- PCR or clinically confirmed Covid-19
Exclusion Criteria
- Severe pulmonary disease
- Severe cardiovascular disease
- Severe hepatic disease
- Severe renal disease
- Diabetes mellitus type one
- Metabolic acidosis
- Oxygen saturation <70%
- Pregnancy
- Breast feeding
- Concomitant treatment with anticoagulation drugs
- Concomitant treatment with CYP3A4 medicines with narrow therapeutic window
Data sourced from ClinicalTrials.gov (NCT05017493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.